1
|
Abdellaoui M, Oppel K, Vianna A, Soleilhavoup M, Yan X, Melaimi M, Bertrand G. 1 H-1,2,3-Triazol-5-ylidenes as Catalytic Organic Single-Electron Reductants. J Am Chem Soc 2024; 146:2933-2938. [PMID: 38253007 DOI: 10.1021/jacs.3c14360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2024]
Abstract
Most of the known single-electron reductants are either metal based reagents, used in a stoichiometric amount, or a combination of an organic species and a photocatalyst. Here we report that 1H-1,2,3-triazol-5-ylidenes act not only as stoichiometric one-electron donors but also as catalytic organic reducing agents, without the need of a photocatalyst. As a proof of concept, we studied the reduction of quinones, which are well-known electron conveyors that are involved in various biological and industrial processes. This work also provides experimental evidence for the formation of a bis(triazolium)carbonate adduct, which acts as the resting state of the catalytic cycle and as the carbene reservoir.
Collapse
Affiliation(s)
- Mehdi Abdellaoui
- UCSD-CNRS Joint Research Laboratory (IRL3555), Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, California 92093-0358, United States
| | - Kai Oppel
- UCSD-CNRS Joint Research Laboratory (IRL3555), Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, California 92093-0358, United States
| | - Adam Vianna
- UCSD-CNRS Joint Research Laboratory (IRL3555), Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, California 92093-0358, United States
| | - Michele Soleilhavoup
- UCSD-CNRS Joint Research Laboratory (IRL3555), Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, California 92093-0358, United States
| | - Xiaoyu Yan
- Key Laboratory of Advanced Light Conversion Materials and Biophotonics, Department of Chemistry, Renmin University of China, Beijing,100872, China
| | - Mohand Melaimi
- UCSD-CNRS Joint Research Laboratory (IRL3555), Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, California 92093-0358, United States
| | - Guy Bertrand
- UCSD-CNRS Joint Research Laboratory (IRL3555), Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, California 92093-0358, United States
| |
Collapse
|
2
|
Włodarczyk J, Krajewska J, Talar M, Szeleszczuk Ł, Gurba A, Lipiec S, Taciak P, Szczepaniak R, Młynarczuk-Biały I, Fichna J. New gold(III) complexes TGS 121, 404, and 702 show anti-tumor activity in colitis-induced colorectal cancer: an in vitro and in vivo study. Pharmacol Rep 2024; 76:127-139. [PMID: 38082190 PMCID: PMC10830623 DOI: 10.1007/s43440-023-00558-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2023] [Revised: 11/10/2023] [Accepted: 11/13/2023] [Indexed: 02/02/2024]
Abstract
BACKGROUND Chronic inflammation in the course of inflammatory bowel disease may result in colon cancer, or colitis-associated colorectal cancer (CACRC). It is well established that CACRC is associated with oxidative stress and secretion of multiple pro-inflammatory cytokines, e.g. tumor necrosis factor-α. Recently, we proved that the administration of gold(III) complexes resulted in the alleviation of acute colitis in mice. The aim of the current study was to assess the antitumor effect of a novel series of gold(III) complexes: TGS 121, 404, 512, 701, 702, and 703. MATERIALS Analyzed gold(III) complexes were screened in the in vitro studies using colorectal cancer and normal colon epithelium cell lines, SW480, HT-29, and CCD 841 CoN, and in vivo, in the CACRC mouse model. RESULTS Of all tested complexes, TGS 121, 404, and 702 exhibited the strongest anti-tumor effect in in vitro viability assay of colon cancer cell lines and in in vivo CACRC model, in which these complexes decreased the total number of colonic tumors and macroscopic score. We also evidenced that the mechanism of action was linked to the enzymatic antioxidant system and inflammatory cytokines. CONCLUSIONS TGS 121, 404, and 702 present anti-tumor potential and are an attractive therapeutic option for colorectal cancer.
Collapse
Affiliation(s)
- Jakub Włodarczyk
- Department of Biochemistry, Chair of Biochemistry and Chemistry, Faculty of Medicine, Medical University of Łódź, Mazowiecka 5, 92-215, Lodz, Poland
- Department of General and Oncological Surgery, Faculty of Medicine, Medical University of Łódź, Pomorska 251, 92-213, Lodz, Poland
| | - Julia Krajewska
- Department of Biochemistry, Chair of Biochemistry and Chemistry, Faculty of Medicine, Medical University of Łódź, Mazowiecka 5, 92-215, Lodz, Poland
| | - Marcin Talar
- Department of Biochemistry, Chair of Biochemistry and Chemistry, Faculty of Medicine, Medical University of Łódź, Mazowiecka 5, 92-215, Lodz, Poland
| | - Łukasz Szeleszczuk
- Department of Organic and Physical Chemistry, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1, 02-093, Warsaw, Poland
| | - Agata Gurba
- Department of Pharmacodynamics, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1 Str., 02-093, Warsaw, Poland
| | - Szymon Lipiec
- HESA at the Department for Histology and Embryology, Medical University of Warsaw, Chałubińskiego 5, 02-004, Warsaw, Poland
| | - Przemysław Taciak
- Department of Pharmacodynamics, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1 Str., 02-093, Warsaw, Poland
| | | | - Izabela Młynarczuk-Biały
- Department for Histology and Embryology, Medical University of Warsaw, Chałubińskiego 5, 02-004, Warsaw, Poland
| | - Jakub Fichna
- Department of Biochemistry, Chair of Biochemistry and Chemistry, Faculty of Medicine, Medical University of Łódź, Mazowiecka 5, 92-215, Lodz, Poland.
| |
Collapse
|
3
|
Mironov IV, Kharlamova VY, Makotchenko EV. Some remarks on the biological application of gold(III) complexes. Biometals 2024; 37:233-246. [PMID: 37855996 DOI: 10.1007/s10534-023-00545-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2023] [Accepted: 09/23/2023] [Indexed: 10/20/2023]
Abstract
Gold(III) complexes are widely studied as antitumor agents and show good results. The interaction with biologically active thiols (thiomalate, cysteine, glutathione (GSH) and human serum albumin) of a number of gold(III) complexes with N-containing polydentate ligands in aqueous solution with pH 7.4 and 0.2 M NaCl was studied. Complexes with 1,10-phenanthroline and 2,2'-bipyridyl, Au(phen)(OH)2+ and Au(bipy)(OH)2+, react fast with an excess of any of these thiols and in less than a few seconds transform into gold(I) bis-thiolate complexes. For complexes with deprotonated ethylenediamine and diethylenetriamine, Au(en)(en-H)2+ and Au(dien-H)(Cl,OH)+, at a significant excess of GSH, a relatively long-lived gold(III) complex AuIII(GSH)iLj is formed. At t = 37 °C, it transforms into the gold(I) bis-thiolate complex Au(GSH)2 by 90% in 4 h. However, for other thiols, the rate of decomposition of similar complexes is about 10 times higher. Some other complexes were also considered. In all cases, a fairly fast reduction of gold(III) to gold(I) occurs with the formation of the gold(I) bis-thiolates.
Collapse
Affiliation(s)
- Igor V Mironov
- Nikolaev Institute of Inorganic Chemistry SB RAS, 3 Lavrentiev Avenue, Novosibirsk, 630090, Russia.
| | - Viktoria Yu Kharlamova
- Nikolaev Institute of Inorganic Chemistry SB RAS, 3 Lavrentiev Avenue, Novosibirsk, 630090, Russia
| | - Eugenia V Makotchenko
- Nikolaev Institute of Inorganic Chemistry SB RAS, 3 Lavrentiev Avenue, Novosibirsk, 630090, Russia
| |
Collapse
|
4
|
Mertens RT, Gukathasan S, Arojojoye AS, Olelewe C, Awuah SG. Next Generation Gold Drugs and Probes: Chemistry and Biomedical Applications. Chem Rev 2023; 123:6612-6667. [PMID: 37071737 PMCID: PMC10317554 DOI: 10.1021/acs.chemrev.2c00649] [Citation(s) in RCA: 18] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/20/2023]
Abstract
The gold drugs, gold sodium thiomalate (Myocrisin), aurothioglucose (Solganal), and the orally administered auranofin (Ridaura), are utilized in modern medicine for the treatment of inflammatory arthritis including rheumatoid and juvenile arthritis; however, new gold agents have been slow to enter the clinic. Repurposing of auranofin in different disease indications such as cancer, parasitic, and microbial infections in the clinic has provided impetus for the development of new gold complexes for biomedical applications based on unique mechanistic insights differentiated from auranofin. Various chemical methods for the preparation of physiologically stable gold complexes and associated mechanisms have been explored in biomedicine such as therapeutics or chemical probes. In this Review, we discuss the chemistry of next generation gold drugs, which encompasses oxidation states, geometry, ligands, coordination, and organometallic compounds for infectious diseases, cancer, inflammation, and as tools for chemical biology via gold-protein interactions. We will focus on the development of gold agents in biomedicine within the past decade. The Review provides readers with an accessible overview of the utility, development, and mechanism of action of gold-based small molecules to establish context and basis for the thriving resurgence of gold in medicine.
Collapse
Affiliation(s)
- R Tyler Mertens
- Department of Chemistry, University of Kentucky, Lexington, Kentucky 40506, United States
| | - Sailajah Gukathasan
- Department of Chemistry, University of Kentucky, Lexington, Kentucky 40506, United States
| | - Adedamola S Arojojoye
- Department of Chemistry, University of Kentucky, Lexington, Kentucky 40506, United States
| | - Chibuzor Olelewe
- Department of Chemistry, University of Kentucky, Lexington, Kentucky 40506, United States
| | - Samuel G Awuah
- Department of Chemistry, University of Kentucky, Lexington, Kentucky 40506, United States
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky 40536, United States
- University of Kentucky Markey Cancer Center, Lexington, Kentucky 40536, United States
| |
Collapse
|
5
|
Pimenov OA, Grazhdan KV, Zavalishin MN, Gamov GA. Geometry and UV-Vis Spectra of Au 3+ Complexes with Hydrazones Derived from Pyridoxal 5'-Phosphate: A DFT Study. Int J Mol Sci 2023; 24:ijms24098412. [PMID: 37176119 PMCID: PMC10179053 DOI: 10.3390/ijms24098412] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2023] [Revised: 05/05/2023] [Accepted: 05/06/2023] [Indexed: 05/15/2023] Open
Abstract
Gold(III) complexes with different ligands can provide researchers with a measure against pathogenic microorganisms with antibiotic resistance. We reported in our previous paper that the UV-Vis spectra of different protonated species of complexes formed by gold(III) and five hydrazones derived from pyridoxal 5'-phosphate are similar to each other and to the spectra of free protonated hydrazones. The present paper focuses on the reasons of the noted similarity in electron absorption spectra. The geometry of different protonated species of complexes of gold(III) and hydrazones (15 structures in total) was optimized using the density functional theory (DFT). The coordination polyhedron of gold(III) bond critical points were further studied to identify the symmetry of the gold coordination sphere and the type of interactions that hold the complex together. The UV-Vis spectra were calculated using TD DFT methods. The molecular orbitals were analyzed to interpret the calculated spectra.
Collapse
Affiliation(s)
- Oleg A Pimenov
- General Chemical Technology Department, Ivanovo State University of Chemistry and Technology, Sheremetevskii pr. 7, 153000 Ivanovo, Russia
| | - Konstantin V Grazhdan
- General Chemical Technology Department, Ivanovo State University of Chemistry and Technology, Sheremetevskii pr. 7, 153000 Ivanovo, Russia
| | - Maksim N Zavalishin
- General Chemical Technology Department, Ivanovo State University of Chemistry and Technology, Sheremetevskii pr. 7, 153000 Ivanovo, Russia
| | - George A Gamov
- General Chemical Technology Department, Ivanovo State University of Chemistry and Technology, Sheremetevskii pr. 7, 153000 Ivanovo, Russia
| |
Collapse
|
6
|
Moreno-Alcántar G, Picchetti P, Casini A. Gold Complexes in Anticancer Therapy: From New Design Principles to Particle-Based Delivery Systems. Angew Chem Int Ed Engl 2023; 62:e202218000. [PMID: 36847211 DOI: 10.1002/anie.202218000] [Citation(s) in RCA: 22] [Impact Index Per Article: 22.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2022] [Revised: 02/26/2023] [Accepted: 02/27/2023] [Indexed: 02/28/2023]
Abstract
The discovery of the medicinal properties of gold complexes has fuelled the design and synthesis of new anticancer metallodrugs, which have received special attention due to their unique modes of action. Current research in the development of gold compounds with therapeutic properties is predominantly focused on the molecular design of drug leads with superior pharmacological activities, e.g., by introducing targeting features. Moreover, intensive research aims at improving the physicochemical properties of gold compounds, such as chemical stability and solubility in the physiological environment. In this regard, the encapsulation of gold compounds in nanocarriers or their chemical grafting onto targeted delivery vectors could lead to new nanomedicines that eventually reach clinical applications. Herein, we provide an overview of the state-of-the-art progress of gold anticancer compounds, andmore importantly we thoroughly revise the development of nanoparticle-based delivery systems for gold chemotherapeutics.
Collapse
Affiliation(s)
- Guillermo Moreno-Alcántar
- Chair of Medicinal and Bioinorganic Chemistry, School of Natural Sciences, Department of Chemistry, Technical University of Munich (TUM), Lichtenbergstr. 4, 85748, Garching b. München, Germany
| | - Pierre Picchetti
- Karlsruhe Institute of Technology (KIT), Institute of Nanotechnology, Hermann-von-Helmholtz-Platz 1, 76344, Eggenstein-Leopoldshafen, Germany
| | - Angela Casini
- Chair of Medicinal and Bioinorganic Chemistry, School of Natural Sciences, Department of Chemistry, Technical University of Munich (TUM), Lichtenbergstr. 4, 85748, Garching b. München, Germany
| |
Collapse
|
7
|
4-Amino-5-benzoyl-1-benzyl-2-(4,5,6,7-tetrahydro-1H-indol-2-yl)-1H-pyrrole-3-carbonitrile. MOLBANK 2023. [DOI: 10.3390/m1547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
The title compound, 4-amino-5-benzoyl-1-benzyl-2-(4,5,6,7-tetrahydro-1H-indol-2-yl)- 1H-pyrrole-3-carbonitrile, was synthesized for the first time in a 40% yield by the reaction of N-benzyl-3-imino-5,6,7,8-tetrahydro-3H-pyrrolo[1,2-a]indol-1-amine and 1-chloroacetophenone in a K2CO3/MeCN system (reflux, 6 h). The product was characterized by 1H-NMR, 13C-NMR, IR spectroscopy, and elemental analysis.
Collapse
|
8
|
Khan HA, Al‐Hoshani A, Isab AA, Alhomida AS. A Gold(III) Complex with Potential Anticancer Properties. ChemistrySelect 2022. [DOI: 10.1002/slct.202202956] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022]
Affiliation(s)
- Haseeb A. Khan
- FRCPath, FRSC Department of Biochemistry College of Science King Saud University P.O. Box 2455 Riyadh 11451 Saudi Arabia
| | - Ali Al‐Hoshani
- Department of Pharmaceutical Chemistry College of Pharmacy King Saud University Riyadh 11451 Saudi Arabia
| | - Anvarhusein A. Isab
- Department of Chemistry College of Science King Fahd University of Petroleum and Minerals Dhahran Saudi Arabia
| | - Abdullah S. Alhomida
- FRCPath, FRSC Department of Biochemistry College of Science King Saud University P.O. Box 2455 Riyadh 11451 Saudi Arabia
| |
Collapse
|
9
|
The role of tridentate ligands on the redox stability of anticancer gold(III) complexes. J Inorg Biochem 2022; 236:111970. [PMID: 36049259 DOI: 10.1016/j.jinorgbio.2022.111970] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2022] [Revised: 08/12/2022] [Accepted: 08/13/2022] [Indexed: 12/15/2022]
Abstract
Gold(III) complexes are promising compounds for cancer chemotherapy, whose action depends on their redox stability. In this context, the choice of ligands is crucial to adjust their reactivity and biological response. The present study addressed the effect of the gold coordination sphere on the reduction potential (Eo) for ten gold(III) complexes containing five or six-membered rings tridentate ligands - [AuIII(trident)Cl]3+n (trident = N^N^N, C^N^N, C^C^N, C^N^C, and N^C^N). The calculated Eo covered a broad range of 2500 mV with the most stable complexes containing two AuC bonds (Eo = -1.85 V for [AuIII(C^C^N)Cl] - f). For complexes with one AuC bond, the N^C^N ligands stabilize the gold(III) complex more efficiently than N^N^C; however, the inclusion of the non-innocent ligand bipy (2,2'-bipyridine) in N^N portion provides an extra stabilization effect. Among the derivatives with one AuC bond, [AuIII(N^N^C)Cl]+ (N^N = bipy) (a) showed Eo = -1.20 V. For the complexes with N^N^N ligands, Eo was positive and almost constant (+0.60 V). Furthermore, the kinetics for ligand exchange reactions (Cl-/H2O, H2O/Cys and Cl-/Cys) were monitored for the most stable compounds and the energy profiles compared to the reduction pathways.
Collapse
|
10
|
Lu Y, Ma X, Chang X, Liang Z, Lv L, Shan M, Lu Q, Wen Z, Gust R, Liu W. Recent development of gold(I) and gold(III) complexes as therapeutic agents for cancer diseases. Chem Soc Rev 2022; 51:5518-5556. [PMID: 35699475 DOI: 10.1039/d1cs00933h] [Citation(s) in RCA: 54] [Impact Index Per Article: 27.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Metal complexes have demonstrated significant antitumor activities and platinum complexes are well established in the clinical application of cancer chemotherapy. However, the platinum-based treatment of different types of cancers is massively hampered by severe side effects and resistance development. Consequently, the development of novel metal-based drugs with different mechanism of action and pharmaceutical profile attracts modern medicinal chemists to design and synthesize novel metal-based agents. Among non-platinum anticancer drugs, gold complexes have gained considerable attention due to their significant antiproliferative potency and efficacy. In most situations, the gold complexes exhibit anticancer activities by targeting thioredoxin reductase (TrxR) or other thiol-rich proteins and enzymes and trigger cell death via reactive oxygen species (ROS). Interestingly, gold complexes were recently reported to elicit biochemical hallmarks of immunogenic cell death (ICD) as an ICD inducer. In this review, the recent progress of gold(I) and gold(III) complexes is comprehensively summarized, and their activities and mechanism of action are documented.
Collapse
Affiliation(s)
- Yunlong Lu
- Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
| | - Xiaoyan Ma
- Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
| | - Xingyu Chang
- Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
| | - Zhenlin Liang
- Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
| | - Lin Lv
- Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
| | - Min Shan
- Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
| | - Qiuyue Lu
- Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
| | - Zhenfan Wen
- Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
| | - Ronald Gust
- Institute of Pharmacy/Pharmaceutical Chemistry, University of Innsbruck, Center for Chemistry and Biomedicine, Innsbruck, Austria.
| | - Wukun Liu
- Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China. .,State key Laboratory of Coordination Chemistry, Nanjing University, Nanjing, 210023, China
| |
Collapse
|
11
|
Ratia C, Cepas V, Soengas R, Navarro Y, Velasco-de Andrés M, Iglesias MJ, Lozano F, López-Ortiz F, Soto SM. A C ∧S-Cyclometallated Gold(III) Complex as a Novel Antibacterial Candidate Against Drug-Resistant Bacteria. Front Microbiol 2022; 13:815622. [PMID: 35308343 PMCID: PMC8928146 DOI: 10.3389/fmicb.2022.815622] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2021] [Accepted: 01/13/2022] [Indexed: 12/14/2022] Open
Abstract
The worldwide emergence and spread of infections caused by multidrug-resistant bacteria endangers the efficacy of current antibiotics in the clinical setting. The lack of new antibiotics in the pipeline points to the need of developing new strategies. Recently, gold-based drugs are being repurposed for antibacterial applications. Among them, gold(III) complexes have received increasing attention as metal-based anticancer agents. However, reports on their antibacterial activity are scarce due to stability issues. The present work demonstrates the antibacterial activity of the gold(III) complex 2 stabilized as C∧S-cycloaurated containing a diphenylphosphinothioic amide moiety, showing minimum inhibitory concentration (MIC) values that ranged from 4 to 8 and from 16 to 32 mg/L among Gram-positive and Gram-negative multidrug-resistant (MDR) pathogens, respectively. Complex 2 has a biofilm inhibitory activity of only two to four times than its MIC. We also describe for the first time a potent antibacterial synergistic effect of a gold(III) complex combined with colistin, showing a bactericidal effect in less than 2 h; confirming the role of the outer membrane as a permeability barrier. Complex 2 shows a low rate of internalization in Staphylococcus aureus and Acinetobacter baumannii; it does not interact with replication enzymes or efflux pumps, causes ultrastructural damages in both membrane and cytoplasmic levels, and permeabilizes the bacterial membrane. Unlike control antibiotics, complex 2 did not generate resistant mutants in 30-day sequential cultures. We detected lower cytotoxicity in a non-tumoral THLE-2 cell line (IC50 = 25.5 μM) and no acute toxicity signs in vivo after an i.v. 1-mg/kg dose. The characterization presented here reassures the potential of complex 2 as a new chemical class of antimicrobial agents.
Collapse
Affiliation(s)
- Carlos Ratia
- ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain
| | - Virginio Cepas
- ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain
| | - Raquel Soengas
- Área de Química Orgánica, Centro de Investigación CIAIMBITAL, Universidad de Almería, Almería, Spain
| | - Yolanda Navarro
- Área de Química Orgánica, Centro de Investigación CIAIMBITAL, Universidad de Almería, Almería, Spain
| | - María Velasco-de Andrés
- Immunoreceptors del Sistema Innat i Adaptatiu, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
| | - María José Iglesias
- Área de Química Orgánica, Centro de Investigación CIAIMBITAL, Universidad de Almería, Almería, Spain
| | - Francisco Lozano
- Immunoreceptors del Sistema Innat i Adaptatiu, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
- Servei d’Immunologia, Centre de Diagnòstic Biomèdic, Hospital Clínic de Barcelona, Barcelona, Spain
- Departament de Biomedicina, Universitat de Barcelona, Barcelona, Spain
| | - Fernando López-Ortiz
- Área de Química Orgánica, Centro de Investigación CIAIMBITAL, Universidad de Almería, Almería, Spain
| | - Sara M. Soto
- ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain
| |
Collapse
|
12
|
Marichev KO, Patil SA, Patil SA, Heras Martinez HM, Bugarin A. N-heterocyclic carbene metal complexes as therapeutic agents: a patent review. Expert Opin Ther Pat 2021; 32:47-61. [PMID: 34365884 DOI: 10.1080/13543776.2021.1965992] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
INTRODUCTION Besides the well-established catalytic, synthetic and materials related applications of N-heterocyclic carbene (NHC) metal complexes, their use as therapeutics deserves a special attention. Many literature reports indicate that their bioactivity is superior to other organometallic compounds. The main focus of patent disclosures in this area is the elucidation of anticancer and antimicrobial activities of NHC transition metal complexes. Nonetheless, a variety of other biological activities have been reported in non-patent literature to date. AREA COVERED Patent literature on NHC metal complexes with focus on their therapeutic applications and relationship structure-biological activity disclosed since the first issued patent (2010) up to now (2021). The information was collected from publicly available data sources (e.g. Chemical Abstracts, MedLine, Reaxys, and SciFinder). EXPERT OPINION Although the first reports on biological applications of NHC metal complexes originate in 2000s, the greatest progress in this area was made only in the past decade. A growing number of patent disclosures indicates that structural design of new NHC metal complexes is crucial for their successful use in both medicine and biochemistry. In the next few years, we expect to see more stable and effective NHC metal complexes as potential therapeutic agents and perhaps in clinical trials.
Collapse
Affiliation(s)
| | - Siddappa A Patil
- Centre for Nano and Material Sciences, Jain University, Jain Global Campus, Kanakapura, Ramanagaram, Bangalore, India
| | - Shivaputra A Patil
- Pharmaceutical Sciences Department, College of Pharmacy, Rosalind Franklin University of Medicine & Science, North Chicago, IL, USA
| | | | - Alejandro Bugarin
- Department of Chemistry & Physics, Florida Gulf Coast University, Fort Myers, FL, USA
| |
Collapse
|
13
|
Kim JH, Ofori S, Parkin S, Vekaria H, Sullivan PG, Awuah SG. Anticancer gold(iii)-bisphosphine complex alters the mitochondrial electron transport chain to induce in vivo tumor inhibition. Chem Sci 2021; 12:7467-7479. [PMID: 34163837 PMCID: PMC8171344 DOI: 10.1039/d1sc01418h] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2021] [Accepted: 04/16/2021] [Indexed: 01/10/2023] Open
Abstract
Expanding the chemical diversity of metal complexes provides a robust platform to generate functional bioactive reagents. To access an excellent repository of metal-based compounds for probe/drug discovery, we capitalized on the rich chemistry of gold to create organometallic gold(iii) compounds by ligand tuning. We obtained novel organogold(iii) compounds bearing a 1,2-bis(diphenylphosphino)benzene ligand, providing structural diversity with optimal physiological stability. Biological evaluation of the lead compound AuPhos-89 demonstrates mitochondrial complex I-mediated alteration of the mitochondrial electron transport chain (ETC) to drive respiration and diminish cellular energy in the form of adenosine triphosphate (ATP). Mechanism-of-action efforts, RNA-Seq, quantitative proteomics, and NCI-60 screening reveal a highly potent anticancer agent that modulates mitochondrial ETC. AuPhos-89 inhibits the tumor growth of metastatic triple negative breast cancer and represents a new strategy to study the modulation of mitochondrial respiration for the treatment of aggressive cancer and other disease states where mitochondria play a pivotal role in the pathobiology.
Collapse
Affiliation(s)
- Jong Hyun Kim
- Department of Chemistry, University of Kentucky Lexington KY 40506 USA
| | - Samuel Ofori
- Department of Chemistry, University of Kentucky Lexington KY 40506 USA
| | - Sean Parkin
- Department of Chemistry, University of Kentucky Lexington KY 40506 USA
| | - Hemendra Vekaria
- Spinal Cord and Brain Injury Research Center, University of Kentucky USA
- Department of Neuroscience, University of Kentucky USA
| | - Patrick G Sullivan
- Spinal Cord and Brain Injury Research Center, University of Kentucky USA
- Department of Neuroscience, University of Kentucky USA
- Lexington Veterans' Affairs Healthcare System USA
| | - Samuel G Awuah
- Department of Chemistry, University of Kentucky Lexington KY 40506 USA
- Center for Pharmaceutical Research and Innovation, College of Pharmacy and Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky Lexington Kentucky 40536 USA
| |
Collapse
|